Due to the important roles of VEGF-A165/NRP-1/VEGFR-2 in tumor angiogenesis, we propose that interrupting VEGF-A165 binding to VEGFR-2 or NRP-1 may be a practical method for anti-angiogenic therapy. Here, KDR is linked to neoplasm.